KarenSmithMD

Oncology • Washington, DC

Breast Cancer

Physician

Join to view full profile

Dr. Smith is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Smith's full profile

Already have an account?

Office
5255 Loughboro Road, NW
1st Floor
Washington, DC 20016
Phone+1 202-660-6500

Fax+1 202-660-6501

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
Rush Medical College of Rush University Medical CenterClass of 1998

Certifications & Licensure

VA State Medical License 2020 - 2026
MD State Medical License 2002 - 2025
DC State Medical License 2006 - 2024
NY State Medical License 2003 - 2006
PA State Medical License 1999 - 2002
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
Yuqing Liang, Christina L Gersch, Jennifer Lehman, N Lynn Henry, Karen Lisa Smith
Pharmacogenetics and Genomics. 2024-06-01
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131.
Karen L Smith, Fengmin Zhao, Ingrid A Mayer, Amye J Tevaarwerk, Sofia F Garcia
Cancer. 2024-05-15
Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation.
Ilia Rattsev, Vered Stearns, Amanda L Blackford, Daniel L Hertz, Karen L Smith
JAMIA Open. 2024-04-01

Press Mentions

Know What Your Doctors Know: Mestastatic Breast Cancer Webinar October 2018September 29th, 2018
Jazz Pharmaceuticals Completes Rolling Submission of New Drug Application for Vyxeos™ (CPX-351), an Investigational Treatment for Acute Myeloid LeukemiaApril 3rd, 2017
Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in NarcolepsyMarch 15th, 2017
Join now to see all